Enter your email address
Submit
Write your message
Volume 15, Issue 2 (Iranian Journal of Breast Diseases 2022)
ijbd 2022, 15(2): 74-85 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Adnan Yousif B, Abdulkadhum Nasser H, Abd Ali Shihad A. Association Between Oncotype DX Recurrence Score and Clinicopathological Variables in Breast Cancer Patients. ijbd 2022; 15 (2) :74-85
URL: http://ijbd.ir/article-1-964-en.html
URL: http://ijbd.ir/article-1-964-en.html
1- M.B.Ch.B, FICMS, Diwaniya Teaching, Hospital, Iraq , bahaulddin@gmail.com
2- M.B.Ch.B, FICMS, Imam Al_Hussain Medical City, Iraq
3- M.B.Ch.B, FICMS, Diwaniya Teaching, Hospital, Iraq
2- M.B.Ch.B, FICMS, Imam Al_Hussain Medical City, Iraq
3- M.B.Ch.B, FICMS, Diwaniya Teaching, Hospital, Iraq
Abstract: (2159 Views)
Introduction: Breast cancer is the most common cancer and the leading cause of cancer-related death in women. Clinicopathological variables are important factors in deciding on breast cancer treatment. This study evaluated the association between the recurrence score generated by the Oncotype DX® 21-gene assay and classic clinicopathological variables.
Methods: A single-institution retrospective study on 44 Iraqi breast cancer patients was conducted using the Oncotype DX test at Baghdad Oncology Teaching Hospital. Patients positive for estrogen receptor and negative for ERBB2 (HER2/neu) were included. The cases were divided into three groups of low-, intermediate-, and high-risk according to the Oncotype DX Breast Recurrence Risk Score and were compared on clinicopathological variables.
Results: Of the 44 women included in this study, low, intermediate, and high recurrence scores were noted in 16 (36.4%), 16 (36.4%), and 12 (27.2%) patients, respectively. The mean age of participants was 49.3 years, and the median size of the tumor was 2.3 cm. None of the examined clinicopathological variables were statistically associated with the recurrence risk score.
Conclusion: This study indicated that standard clinicopathological variables are not good predictors of early-stage breast cancer recurrence. Because of the high cost of the Oncotype DX test, its incorporation in breast cancer protocols needs stronger evidence.
Methods: A single-institution retrospective study on 44 Iraqi breast cancer patients was conducted using the Oncotype DX test at Baghdad Oncology Teaching Hospital. Patients positive for estrogen receptor and negative for ERBB2 (HER2/neu) were included. The cases were divided into three groups of low-, intermediate-, and high-risk according to the Oncotype DX Breast Recurrence Risk Score and were compared on clinicopathological variables.
Results: Of the 44 women included in this study, low, intermediate, and high recurrence scores were noted in 16 (36.4%), 16 (36.4%), and 12 (27.2%) patients, respectively. The mean age of participants was 49.3 years, and the median size of the tumor was 2.3 cm. None of the examined clinicopathological variables were statistically associated with the recurrence risk score.
Conclusion: This study indicated that standard clinicopathological variables are not good predictors of early-stage breast cancer recurrence. Because of the high cost of the Oncotype DX test, its incorporation in breast cancer protocols needs stronger evidence.
Type of Study: Research |
Received: 2022/01/31 | Accepted: 2022/02/8 | Published: 2022/07/16
Received: 2022/01/31 | Accepted: 2022/02/8 | Published: 2022/07/16
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
